Mock Donald M, Widness John A, Veng-Pedersen Peter, Strauss Ronald G, Cancelas Jose A, Cohen Robert M, Lindsell Christopher J, Franco Robert S
Departments of Biochemistry & Molecular Biology and Pediatrics, The University of Arkansas for Medical Sciences, Little Rock, AR.
Department of Pediatrics, The University of Iowa, Iowa City, IA.
Transfus Med Rev. 2014 Jul;28(3):114-25. doi: 10.1016/j.tmrv.2014.03.003. Epub 2014 Apr 5.
The goal of this review is to summarize and critically assess information concerning the biotin method to label red blood cells (RBC) for use in studies of RBC and transfusion biology-information that will prove useful to a broad audience of clinicians and scientists. A review of RBC biology, with emphasis on RBC senescence and in vivo survival, is included, followed by an analysis of the advantages and disadvantages of biotin-labeled RBC (BioRBC) for measuring circulating RBC volume, posttransfusion RBC recovery, RBC life span, and RBC age-dependent properties. The advantages of BioRBC over (51)Cr RBC labeling, the current reference method, are discussed. Because the biotin method is straightforward and robust, including the ability to follow the entire life spans of multiple RBC populations concurrently in the same subject, BioRBC offers distinct advantages for studying RBC biology and physiology, particularly RBC survival. The method for biotin labeling, validation of the method, and application of BioRBCs to studies of sickle cell disease, diabetes, and anemia of prematurity are reviewed. Studies documenting the safe use of BioRBC are reviewed; unanswered questions requiring future studies, remaining concerns, and regulatory barriers to broader application of BioRBC including adoption as a new reference method are also presented.
本综述的目的是总结并批判性地评估有关生物素标记红细胞（RBC）用于红细胞和输血生物学研究的信息，这些信息将对广大临床医生和科学家有用。本文包括对红细胞生物学的综述，重点是红细胞衰老和体内存活，随后分析生物素标记红细胞（BioRBC）在测量循环红细胞体积、输血后红细胞恢复、红细胞寿命以及红细胞年龄依赖性特性方面的优缺点。讨论了BioRBC相对于当前参考方法（51）Cr红细胞标记的优势。由于生物素方法简单且可靠，包括能够在同一受试者中同时跟踪多个红细胞群体的整个寿命，BioRBC在研究红细胞生物学和生理学，特别是红细胞存活方面具有明显优势。本文综述了生物素标记方法、该方法的验证以及BioRBC在镰状细胞病、糖尿病和早产儿贫血研究中的应用。还综述了记录BioRBC安全使用的研究；提出了需要未来研究解答的未决问题、尚存的担忧以及BioRBC更广泛应用的监管障碍，包括作为新参考方法被采用的障碍。
